[Effects of alpha1 adrenoceptor antagonist, naftopidil, on non-bacterial chronic pelvic pain syndrome in patients with lower urinary tract syndrome: evaluation of its efficacy using NIH-CPSI after 4-week treatment].

We investigated the effect of naftopidil an alpha1 adrenoceptor antagonist on non-bacterial chronic pelvic pain syndrome (CPPS) in middle-aged and older male patients with lower urinary tract symptoms (LUTS). Patients who had given informed consent were treated with naftopidil (daily 50 mg), and were evaluated using the Japanese edition of NIH chronic prostatitis symptom index (NIH-CPSI) and the international prostate symptom score (IPSS) at 2 and 4 weeks after the administration. The NIH-CPSI (total score) was significantly improved by naftopidil for 4 weeks (11.

[Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].

Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months. Changes in total/each International Prostate Symptom Score (IPSS) for irritative and obstructive symptoms, nocturia, and residual urine volume were compared before and after its administration. As a result, a significant decrease of score was found in total-IPSS, obstructive and irritative symptoms, which also showed a tendency to decrease at the end of the first month.